Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
XY-4 is a derivative of 1-palmitoyl-2-hydroxy-sn-glycero-3-PA (1-palmitoyl LPA; Item No. 10010094) and an agonist of peroxisome proliferator-activated receptor γ (PPARγ).1 It induces reporter gene expression in RAW 264.7 macrophages expressing a peroxisome proliferator-response element (PPRE) when used at a concentration of 5 µM. XY-4 does not act as an agonist at lysophosphatidic acid receptor 1 (LPA1), LPA2, or LPA3. It induces platelet aggregation in vitro when used at a concentration of 1 µM.2 XY-4 induces carotid artery neointima formation in rats.3
WARNING This product is not for human or veterinary use.
1. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist. Proc. Natl. Acad. Sci. USA 100(1), 131-136 (2003).
2. Synthesis of monofluorinated analogues of lysophosphatidic acid. The Journal of Organic Chemistry 68(13), 5320-5330 (2003).
3. Lysophosphatidic acid induces neointima formation through PPARγ activation. J. Exp. Med. 199(6), 763-774 (2004).